A collaborative research team led by Baylor College of Medicine has identified a significant molecular mechanism behind treatment resistance in triple-negative breast cancer (TNBC). The study, published in Molecular Cancer Therapeutics, focuses on the role of DNA ligase I (LIG1) in tumors carrying TP53 mutations.
Understanding Resistance
The research reveals that the loss of a single copy of the LIG1 gene allows TNBC cells to develop resistance to standard chemotherapy, specifically platinum-based treatments. This genetic alteration has historically made these aggressive cancers much harder to treat effectively.
A New Therapeutic Strategy
By uncovering the underlying molecular pathways triggered by LIG1 loss, the team identified a specific vulnerability. Using animal models, researchers demonstrated that combining existing, available drugs could neutralize this resistance and significantly reduce tumor growth. This discovery offers a potential roadmap for repurposing current medications to treat resistant TNBC cases.
Clinical Implications
Beyond providing a new treatment strategy, the study emphasizes the importance of LIG1 status as a biomarker. Scientists suggest that screening for LIG1 could serve as a vital stratification factor for patients in ongoing and future clinical trials, ensuring that individuals receive the most effective therapies based on their specific genetic profile.
